262 related articles for article (PubMed ID: 25833301)
21. Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor.
Wang Y; Liu A; Xu T; Yin J; Chen W
Clin Med Insights Oncol; 2022; 16():11795549221109500. PubMed ID: 35875418
[TBL] [Abstract][Full Text] [Related]
22. Liquid extramedullary disease in multiple myeloma strongly predicts a poor prognosis and is associated with bortezomib resistance gene upregulation.
Ji J; Guo R; Ma J; Cui Y; Li Y; Sun Z; Li J; Fan L; Qu X
Clin Chim Acta; 2023 Aug; 548():117497. PubMed ID: 37479009
[TBL] [Abstract][Full Text] [Related]
23. Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
Kumar AK; Dakhil C; Teeka Satyan M; Haideri N
J Med Case Rep; 2014 Sep; 8():299. PubMed ID: 25200389
[TBL] [Abstract][Full Text] [Related]
24. Cytogenetic and survival analysis in 315 multiple myeloma patients; five with orbital and eight with extramedullary disease.
Tucker SM; Zaihra T
Orbit; 2023 Dec; 42(6):603-611. PubMed ID: 36697375
[TBL] [Abstract][Full Text] [Related]
25. Advances in the treatment of extramedullary disease in multiple myeloma.
Li Y; Sun Z; Qu X
Transl Oncol; 2022 Aug; 22():101465. PubMed ID: 35679743
[TBL] [Abstract][Full Text] [Related]
26. Genetic Abnormalities in Extramedullary Multiple Myeloma.
McAvera R; Quinn J; Murphy P; Glavey S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511018
[TBL] [Abstract][Full Text] [Related]
27. 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study.
Gao S; Dong F; Yang P; Chen Y; Wang Y; Wang J; Shi Y; Jing H
Ann Hematol; 2024 Jun; 103(6):1979-1987. PubMed ID: 38206369
[TBL] [Abstract][Full Text] [Related]
28. Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.
Katodritou E; Terpos E; Kastritis E; Delimpasis S; Symeonidis AS; Repousis P; Kyrtsonis MC; Vadikolia C; Michalis E; Polychronidou G; Michael M; Papadaki S; Papathanasiou M; Kokoviadou K; Kioumi A; Vlachaki E; Hadjiaggelidou C; Kouraklis A; Patsias I; Gavriatopoulou M; Kotsopoulou M; Verrou E; Gastari V; Christoulas D; Giannopoulou E; Pouli A; Konstantinidou P; Anagnostopoulos A; Dimopoulos MA
Ann Hematol; 2015 Dec; 94(12):2033-42. PubMed ID: 26420061
[TBL] [Abstract][Full Text] [Related]
29. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
Rosiñol L; Beksac M; Zamagni E; Van de Donk NWCJ; Anderson KC; Badros A; Caers J; Cavo M; Dimopoulos MA; Dispenzieri A; Einsele H; Engelhardt M; Fernández de Larrea C; Gahrton G; Gay F; Hájek R; Hungria V; Jurczyszyn A; Kröger N; Kyle RA; Leal da Costa F; Leleu X; Lentzsch S; Mateos MV; Merlini G; Mohty M; Moreau P; Rasche L; Reece D; Sezer O; Sonneveld P; Usmani SZ; Vanderkerken K; Vesole DH; Waage A; Zweegman S; Richardson PG; Bladé J
Br J Haematol; 2021 Aug; 194(3):496-507. PubMed ID: 33724461
[TBL] [Abstract][Full Text] [Related]
30. Clinical and pathologic analysis of extramedullary tumors after hematopoietic stem cell transplantation.
Huang Q; Reddi D; Chu P; Snyder DS; Weisenburger DD
Hum Pathol; 2014 Dec; 45(12):2404-10. PubMed ID: 25294373
[TBL] [Abstract][Full Text] [Related]
31. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.
Short KD; Rajkumar SV; Larson D; Buadi F; Hayman S; Dispenzieri A; Gertz M; Kumar S; Mikhael J; Roy V; Kyle RA; Lacy MQ
Leukemia; 2011 Jun; 25(6):906-8. PubMed ID: 21350560
[TBL] [Abstract][Full Text] [Related]
32. Identification of patients at high risk of secondary extramedullary multiple myeloma development.
Stork M; Sevcikova S; Minarik J; Krhovska P; Radocha J; Pospisilova L; Brozova L; Jarkovsky J; Spicka I; Straub J; Pavlicek P; Jungova A; Jelinek T; Sandecka V; Maisnar V; Hajek R; Pour L
Br J Haematol; 2022 Feb; 196(4):954-962. PubMed ID: 34726261
[TBL] [Abstract][Full Text] [Related]
33. Extramedullary Cardiac Multiple Myeloma-A Case Report and Contemporary Review of the Literature.
Coakley M; Yeneneh B; Rosenthal A; Fonseca R; Mookadam F
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):246-52. PubMed ID: 27009538
[TBL] [Abstract][Full Text] [Related]
34. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Gagelmann N; Eikema DJ; Koster L; Caillot D; Pioltelli P; Lleonart JB; Reményi P; Blaise D; Schaap N; Trneny M; Passweg J; Porras RP; Cahn JY; Musso M; Poiré X; Fenk R; Itälä-Remes M; Pavone V; Fouillard L; Maertens J; Bron D; Pouli A; Schroyens W; Schönland S; Garderet L; Yakoub-Agha I; Kröger N
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2134-2142. PubMed ID: 31288095
[TBL] [Abstract][Full Text] [Related]
35. Autologous stem cell transplantation for multiple myeloma: Long-term results.
Kumar L; Boya RR; Pai R; Harish P; Mookerjee A; Sainath B; Patekar MB; Sahoo RK; Malik PS; Sharma OD; Gupta R
Natl Med J India; 2016; 29(4):192-199. PubMed ID: 28050994
[TBL] [Abstract][Full Text] [Related]
36. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
[TBL] [Abstract][Full Text] [Related]
37. [The therapeutic effect and prognostic value of oligoclonal bands after autologous stem cell transplant in patients with multiple myeloma].
Shi QL; Xu Y; Wang J; Jin YY; Zhang R; Li JY; Chen LJ
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):514-520. PubMed ID: 38317363
[No Abstract] [Full Text] [Related]
38. [Multiple myeloma with myelofibrosis at diagnosis and aggressive extramedullary relapse after autologous stem cell transplantation].
Kodama Y; Saburi M; Kawano K; Uraisami K; Takata H; Miyazaki Y; Wada J; Urabe S; Ohtsuka E
Rinsho Ketsueki; 2024; 65(1):1-6. PubMed ID: 38311382
[TBL] [Abstract][Full Text] [Related]
39. Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.
Chu TH; Jung SH; Kim K; Lee JH; Mun YC; Bang SM; Yoon DH; Lee HS; Min CK; Lee JJ
Ann Hematol; 2022 Jun; 101(6):1217-1226. PubMed ID: 35445844
[TBL] [Abstract][Full Text] [Related]
40. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns.
Danhof S; Rasche L; Mottok A; Steinmüller T; Zhou X; Schreder M; Kilian T; Strifler S; Rosenwald A; Hudecek M; Einsele H; Gerhard-Hartmann E
Ann Hematol; 2021 Jun; 100(6):1537-1546. PubMed ID: 33575947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
